Helping physicians in their efforts to choose tissue-specific therapy

Of the estimated 1.4 million new cancer diagnoses made in the US each year, up to 10% are tumors that are not readily classifiable after an initial diagnostic workup.¹  For these patients, such challenging tumors can be a significant barrier to selection of optimal treatments.

Optimal first-line therapy may include surgery, chemotherapy, radiation, hormonal therapy, or some combination of all of these. Knowing the tissue of origin enables targeted disease management to be put to use in a timely manner. For each of the 15 tissues on Pathwork's Tissue of Origin Test panel, optimal therapy will differ depending on the tumor type.

The panel includes:  colorectal, kidney, thyroid, pancreatic, breast, prostate, gastric, melanoma, bladder, ovarian, hepatocellular, non-Hodgkin's lymphoma, non-small cell lung, sarcoma, and testicular germ cell. 

Current therapy guidelines recommend treatments specific for the primary site of the tumor whenever possible,² yet these guidelines also acknowledge the diagnostic limitations of immunohistochemistry (IHC) and imaging. The Pathwork Tissue of Origin Test supplements these other diagnostic tests and can help the physician in choosing tumor-specific treatments. The accurate, objective information provided by the Pathwork Tissue of Origin Test, FDA-cleared in 2010, can aid clinicians in managing their patients.

References